CAMBRIDGE, Mass. and LOS ANGELES, Dec. 19, 2022 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), today announced that its subsidiary DeepHealth, Inc., a leading developer of artificial intelligence (AI) for mammography interpretation, has received FDA clearance of its mammography density assessment software, Saige-Density™.
Saige-Density™ is a breast density assessment tool that automatically generates an ACR BI-RADS® breast density category, assisting radiologists in making accurate and consistent determinations using AI. The tool helps to reduce the subjectivity inherent in visual analysis.
Almost half of the United States population of women over the age of 40 are considered to have dense breast tissue. Dense breast tissue makes it more difficult for radiologists to detect cancer in a screening mammogram, requiring more attention by the radiologist and potentially indicating additional diagnostic tests. Additionally, women’s risk of developing breast cancer increases as the level of density increases. As a result, 38 U.S. states currently have laws that require screening service providers to alert women about the significance of breast density and, in many cases, provide breast density scores, and the FDA will soon require that all women nationwide be provided density information. Saige-Density™ assists the radiologist in determining this density score with improved accuracy and consistency, which can play an important role in the earlier identification of cancer.
This approval marks the third DeepHealth AI product to receive FDA clearance in less than two years. Saige-Density joins the growing family of dynamic DeepHealth AI tools including Saige-Q™ (a productivity worklist, triage, and prioritization tool) and Saige-Dx™ (a market-leading diagnostic breast cancer screening software that recently showed in a pivotal study to improve performance for all radiologists who used it).
“Achieving FDA clearance for another important tool in the breast cancer screening process in such a short time frame highlights our aggressive commitment to bringing state-of-the-art AI innovation to the breast screening mammography market,” stated Gregory Sorensen, M.D., CEO and co-founder of DeepHealth. “We have developed another one of the most advanced AI algorithms to date to support radiologists in their fight to find breast cancer as early as possible. Our team continues to build on that foundation, and we intend to further innovate and commercialize products that leverage the tremendous advantages of being part of RadNet.”
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 349 owned and/or operated outpatient imaging centers. RadNet’s markets include California, Maryland, Delaware, New Jersey, New York, Florida, and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has approximately 9,000 employees. For more information, visit www.radnet.com.
About DeepHealth, Inc.
DeepHealth, Inc., uses machine learning to distill lifetimes of insights from medical experts into software to assist physicians. DeepHealth’s mission is to enable the best care by providing products that clinicians and patients can trust through rigorous science and clinical integration. For more information, visit www.deep.health.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.
CONTACT:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
DeepHealth, Inc.
Bret Baird
Chief Commercial Officer
480-236-6969
Related Quotes
For a company like Vertex Pharmaceuticals (NASDAQ: VRTX), 10 years isn't a long time. The drug-development process takes between 12 and 14 years, on average, around 8 years of which are devoted to clinical-stage testing and the regulatory-review process.
Heavy advertising and other strategies from Silicon Valley’s playbook boost providers’ growth but not the quality of care.
FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication – the adjunctive treatment of patients with MDD.
AstraZeneca Plc (NASDAQ: AZN) announced topline data from the PEARL Phase 3 trial of Imfinzi (durvalumab) monotherapy versus platinum-based chemotherapy (investigator's choice) as a 1st-line treatment in patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The study did not achieve statistical significance for the primary endpoints of improving overall survival (OS) versus platinum-based chemotherapy as a monotherapy treatment for metastatic NSCLC whose tumor cells express hig
Pharmaceutical companies Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) saw their shares rise 19.6% and 1.7%, respectively, on Tuesday after they announced impressive early results from their mRNA cancer vaccine to prevent melanoma, the deadliest form of skin cancer. This would be a vaccine against cancer, not just against a virus that could cause cancer (like the human papillomavirus and hepatitis B virus vaccines). It's also different from two other "cancer vaccines," Sipuleucel-T and Talimogene laherparepvec, which are used on advanced prostate and melanoma patients, respectively, because this vaccine would be a preventative used on patients who have had prior melanomas excised by surgery and have not yet seen any signs of recurrence.
The parole board’s refusal to free Janet Carter, 69, is part of what advocates warn is a growing humanitarian crisis across the US
The FDA approved AbbVie Inc's (NYSE: ABBV) Vraylar (cariprazine) as an adjunctive therapy to antidepressants for major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant. In addition to being approved as an adjunctive therapy to antidepressants for MDD in adults, it is FDA-approved to treat adults with
The bear market has weighed on stocks across industries this year. Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX) have both climbed in the double digits — and for good reason. Which one of these top stocks represents the better bear market buy right now?
Chinese health authorities on Monday announced two additional COVID-19 deaths, both in the capital Beijing, that were the first reported in weeks and come during an expected surge of illnesses after the nation eased its strict "zero-COVID" approach.
Uganda on Saturday lifted a two-month lockdown on two districts at the epicentre of the country's Ebola epidemic, amid cautious hope that the outbreak could end soon.
"It feels like I'm getting a new email about an outbreak at daycare every week," one mom says. Here's what a pediatrician recommends doing.
Billionaire Elon Musk has frequently spoken about his concerns about underpopulation. He has mentioned that people should focus on having more babies to resolve the problem of low birth rates and population collapse. Earlier this year, Musk shared how the COVID-19 pandemic has resulted in a lower birth rate instead of the "baby boom" expected due to people being forced to stay indoors. Now, a birthing facility could answer Musk's concerns about the world's low birth rates. The world's first arti
Headhunter Candice knows the COVID-19 infections engulfing Beijing and much of China will soon hit her home of Shenzhen city, but she would rather face it without a vaccine booster, saying she fears potential side effects more than the virus. The 28-year-old took two doses of Sinovac's CoronaVac last year, hoping it would make travel easier, but she has since grown more sceptical, citing stories from friends about health impacts, as well as similar health warnings on social media. Candice said she has refused to participate in recent vaccination drives organised by her local community.
The country of 1.4 billion has had some of the strictest COVID containment measures in place since the pandemic began
South Shore Health is grappling with lingering staffing shortages and a full emergency room as people battle a trifecta of respiratory illnesses.
Reverse vaccination teaches the immune system to ignore rather than attack self-proteins. Christoph Burgstedt/Science Photo Library via Getty ImagesAutoimmune conditions like Type 1 diabetes, multiple sclerosis and rheumatoid arthritis arise when an immune system mistakenly attacks its own body’s proteins, cells and organs. Not only do these conditions make the body attack itself, they can also destroy the medications intended to treat them. A reverse vaccination approach my research team and I
Chinese health authorities on Monday announced two additional COVID-19 deaths, both in the capital Beijing, that were the first reported in weeks and come during an expected surge of illnesses after the nation eased its strict “zero-COVID” approach. China had not reported a death from COVID-19 since Dec. 4, even though unofficial reports of a new wave of cases are widespread. With the latest reported deaths, the National Health Commission raised China’s total to 5,237 deaths from COVID-19 in the past three years, out of 380,453 cases of illness — numbers that are much lower than in other major countries but also based on statistics and information-gathering methods that have come into question.
Oregon's trailblazing drug decriminalization law has come under fire amid a slow rollout and rise in overdose deaths. But proponents say much of the criticism is unfair.
Abortion may be illegal in some states, but the longed-for result of overturning Roe — an abortion-free utopia — is not exactly coming to pass.
BEIJING (Reuters) -Streets in major Chinese cities were eerily quiet on Sunday as people stayed home to protect themselves from a surge in COVID-19 cases that has hit urban centres from north to south. China is in the first of an expected three waves of COVID cases this winter, according to the country's chief epidemiologist, Wu Zunyou. China has not reported any COVID deaths since Dec. 7, when it abruptly ended most restrictions key to a zero-COVID tolerance policy following unprecedented public protests.
Leave a Reply
You must be logged in to post a comment.